Pontificia Universidad Javeriana, Cra. 7 # 40-62, Piso 5, Bogotá, Colombia.
Pontificia Universidad Javeriana-Hospital Universitario San Ignacio, Bogotá, Colombia.
Intern Emerg Med. 2023 Mar;18(2):429-437. doi: 10.1007/s11739-022-03186-4. Epub 2023 Feb 15.
In a high proportion of patients, infection by COVID-19 progresses to acute respiratory distress syndrome (ARDS), requiring invasive mechanical ventilation (IMV) and admission to an intensive care unit (ICU). Other devices, such as a high-flow nasal cannula (HFNC), have been alternatives to IMV in settings with limited resources. This study evaluates whether HFNC exposure time prior to IMV is associated with mortality. This observational, analytical study was conducted on a historical cohort of adults with ARDS due to SARS-CoV-2 who were exposed to HFNC and subsequently underwent IMV. Univariate and multivariate logistic regression was used to analyze the impact of HFNC exposure time on mortality, controlling for multiple potential confounders. Of 325 patients with ARDS, 41 received treatment with HFNC for more than 48 h before IMV initiation. These patients had a higher mortality rate (43.9% vs. 27.1%, p: 0.027) than those using HFNC < 48 h. Univariate analysis evidenced an association between mortality and HFNC ≥ 48 h (OR 2.16. 95% CI 1.087-4.287. p: 0.028). Such an association persisted in the multivariable analysis (OR 2.21. 95% CI 1.013-4.808. p: 0.046) after controlling for age, sex, comorbidities, basal severity of infection, and complications. This study also identified a significant increase in mortality after 36 h in HFNC (46.3%, p: 0.003). In patients with ARDS due to COVID-19, HFNC exposure ≥ 48 h prior to IMV is a factor associated with mortality after controlling multiple confounders. Physiological mechanisms for such an association are need to be defined.
在很大比例的患者中,COVID-19 感染进展为急性呼吸窘迫综合征(ARDS),需要进行有创机械通气(IMV)和入住重症监护病房(ICU)。在资源有限的情况下,其他设备,如高流量鼻导管(HFNC),已成为 IMV 的替代方案。本研究评估了在接受 IMV 之前接受 HFNC 的暴露时间是否与死亡率相关。这是一项针对因 SARS-CoV-2 导致 ARDS 的成人的回顾性队列研究,这些患者接受了 HFNC 治疗,随后接受了 IMV。使用单变量和多变量逻辑回归分析 HFNC 暴露时间对死亡率的影响,同时控制了多个潜在混杂因素。在 325 名 ARDS 患者中,有 41 名患者在开始 IMV 前接受 HFNC 治疗超过 48 小时。这些患者的死亡率(43.9%比 27.1%,p:0.027)高于接受 HFNC<48 小时的患者。单变量分析表明,死亡率与 HFNC≥48 小时之间存在关联(OR 2.16,95%CI 1.087-4.287,p:0.028)。在多变量分析中,在控制年龄、性别、合并症、感染基础严重程度和并发症后,这种关联仍然存在(OR 2.21,95%CI 1.013-4.808,p:0.046)。本研究还发现,HFNC 治疗 36 小时后死亡率显著增加(46.3%,p:0.003)。在因 COVID-19 导致 ARDS 的患者中,在接受 IMV 之前接受 HFNC 治疗≥48 小时是在控制多个混杂因素后与死亡率相关的因素。需要确定这种关联的生理机制。